

Short Name	Full Title + Study Description	Type	Investigator	Contact
EMBARK HFpEF	An Exploratory, Open-Label, Proof-of-Concept, Phase 2a Study of Mavacamten (MYK 461) in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF) and Chronic Elevation of Cardiac Troponin I and/or NT-proBNP	Drug	Dr. David Fermin	Katy Wachter Katy.Wachter@spectrumhealth.org 616.486.7481
	<i>This study is for patients who have been diagnosed with heart failure with preserved ejection fraction. This study will test whether the investigational drug, Mavacamten, can lower specific "biomarkers" in patients' blood levels that are signs of heart muscle injury and/or heart wall stress.</i>			
HM3 SWIFT	Implantation of the HeartMate 3 in Subjects with Heart Failure using Surgical Techniques Other Than Full Median Sternotomy	Procedure/ Data Collection	Dr. Marzia Leacche	Katy Wachter Katy.Wachter@spectrumhealth.org 616.486.7481
	<i>This study will be collecting data on patients who undergo implantation of the HeartMate 3 Ventricular Assist Device utilizing techniques other than a full median sternotomy (for example, a thoracotomy, which is an implantation technique for this device that is routinely completed by our cardiac surgery team), and evaluating the impact on post-implant hospital length of stay.</i>			